drugset / Trial / NCT01272245

Omacetaxine and Low Dose Cytarabine in Older Patients With Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (MDS)

NCT01272245

Phase 2 Completed 36 enrolled M.D. Anderson Cancer Center Cephalon · collab
NaSingle-groupOpen-labelTreatment

Summary

The goal of this clinical research study is to learn if omacetaxine given with cytarabine can help to control the disease in patients with AML or high-risk MDS. The safety of the study drugs will also be studied.

Timeline

Start
2011-07
Primary completion
2017-01
Completion
2017-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Cytarabine Small molecule 20 mg Subcutaneous
Subject Omacetaxine Unknown 1.25 mg/m2 Subcutaneous

Indications